TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01620723

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New Breastfeeding Counselling
Description: An intervention will be developed during the first part of the study. The intervention is supposed to consist of evidence based actions to support the metabolic adaptation of the newborn, establishment of the milk production of the mother and increase the breastfeeding self efficacy of the mother.
Study: NCT03585231

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed access to novel novel messaging program intervention
Description: The delayed control intervention uses the novel messaging program for smoking cessation.
Study: NCT00561457

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bard Luminexx Iliac Stent and Delivery System
Description: Iliac Stenting
Study: NCT04458207

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral prosthetic rehabilitation
Description: Individual treatment options will be discussed with the participants individually and rehabilitation will be provided as agreed by the dentist and the participant. The rehabilitation will include fixed prosthodontics. The procedures will involve a control phase involving scaling, root planing oral hygiene instructions etc., extractions and bone augmentation when needed and temporary removable dentures. Restoration of the lost vertical dimension (if needed) with occlusal splints, tooth preparations, placement of dental implants (if needed) and finally cementation of dental crowns. The rehabilitation phase is estimated to take approximately 3-18 months, or more.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral prosthetic rehabilitation
Description: Individual treatment options will be discussed with the participants individually and rehabilitation will be provided as agreed by the dentist and the participant. The rehabilitation will include fixed prosthodontics. The procedures will involve a control phase involving scaling, root planing oral hygiene instructions etc., extractions and bone augmentation when needed and temporary removable dentures. Restoration of the lost vertical dimension (if needed) with occlusal splints, tooth preparations, placement of dental implants (if needed) and finally cementation of dental crowns. The rehabilitation phase is estimated to take approximately 3-18 months, or more.
Study: NCT04139668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone 380 MG [Vivitrol]
Description: Three 4ml intramuscular injections of naltrexone 380mg (Vivitrol) administered over 12 weeks (one injection every 4 weeks)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy and Cognitive Behavioral Therapy
Description: Weekly Motivational Enhancement Therapy and Cognitive Behavioral Therapy (MET/CBT), based upon the Brief Counselling for Marijuana Dependence Manual published by the Substance Abuse and Mental Health Services Administration (SAMHSA), for 12 weeks
Study: NCT03221283

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music therapy group
Description: The experimental group received 13 group music sessions over a three-month period. Different method of music therapy will be used to improve the emotion experience, emotion regulation, emotional control and emotional expression.
Study: NCT01620723

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Health professionals offer the usual care for the breastfeeding mother
Study: NCT02229383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: 2 mg weekly suspension injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Exenatide matching placebo
Description: Once weekly Placebo injection
Study: NCT04057365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is believed to work by attaching to and inhibiting a specific protein in the cancer that controls parts of the immune system (the system in the body that fights off infections and diseases) by shutting down certain immune responses. The investigators believe that nivolumab will inhibit the protein, thus allowing the immune cells to recognize and destroy cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is believed to work by attaching to and inhibiting a specific protein in the cancer that controls parts of the immune system (the system in the body that fights off infections and diseases) by shutting down certain immune responses. The investigators believe that nivolumab will inhibit the protein, thus allowing the immune cells to recognize and destroy cancer cells.
Study: NCT02770248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle
Description: Inactive ingredients used as a placebo for masking purposes
Study: NCT01322919

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supracor
Description: All patients will undergo LASIK treatment on their non-dominant eye with a new laser software algorithm designed to treat both the distance and near vision components.~The developed software algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction. This part of the treatment does not show any difference to a regular LASIK treatment for ametropic cases.~In addition to the treatment for the distance vision a central ablation component will be added to address the near vision.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supracor
Description: All patients will undergo LASIK treatment on their non-dominant eye with a new laser software algorithm designed to treat both the distance and near vision components.~The developed software algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction. This part of the treatment does not show any difference to a regular LASIK treatment for ametropic cases.~In addition to the treatment for the distance vision a central ablation component will be added to address the near vision.
Study: NCT02698241

Intervention type: DEVICE
Group type: OTHER
Intervention: Diagnostic & Medication Management
Description: Single Arm Study. Subjects will be managed using integrated diagnostics.
Study: NCT03809299

Intervention type: OTHER
Group type: OTHER
Intervention: Ad libitum meal timing
Description: Research participants will eat meals provided by the study throughout the day, ad libitum

Intervention type: OTHER
Group type: OTHER
Intervention: Ad libitum meal timing
Description: Research participants will eat meals provided by the study throughout the day, ad libitum

Intervention type: OTHER
Group type: OTHER
Intervention: Twice a day meals
Description: Research participants will eat meals provided by the study at two intervals during the day, and fast in between.

Intervention type: OTHER
Group type: OTHER
Intervention: Twice a day meals
Description: Research participants will eat meals provided by the study at two intervals during the day, and fast in between.
Study: NCT03317535

Intervention type: PROCEDURE
Group type: OTHER
Intervention: General anesthesia
Description: Patients will be injected with propofol, remifentanil and muscular relaxant with controlled ventilation.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Local anesthesia/concious sedation
Description: Patients will be injected with propofol and remifentanil.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Spontaneous breath
Description: Patients will be kept spontaneous breath.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Controlled ventilation
Description: Patient will be kept with controlled ventilation.
Study: NCT02639429

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Misoprostol

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley Balloon + Vaginal Misoprostol
Study: NCT01673113

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zeltiq CoolSculpting device
Description: This is an FDA approved cooling device used for non-invasive and selective reduction of fat around the flanks, an area commonly referred to as the love handles.
Study: NCT04479540

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Angiography scanner
Description: systematic thoracic angiography scanner to diagnose pulmonary embolism and additional blood sample (hemostasis exploration)
Study: NCT01975467

Intervention type: DEVICE
Intervention: CRx
Description: The CRx is used to treat mid-shaft, with or without comminution clavicle fractures.
Study: NCT03332134

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intimate Partner Violence (IPV) Prevention Intervention
Description: The IPV intervention consists of six sessions. Each session will cover one of 6 major modules to enhance transformation of motivation: 1) You, Me, and Us: Spending Meaningful Time Together, 2) I'm a Champion: I Can't Be Broken and I don't Accept Defeat! 3) Building Communication and conflict management strategies, and 4) Empowerment of the Couple: Planning Ahead, 5) Sexual communication and the sexual relationships, and 6) A Lens into Domestic Violence. The sessions will be audio-recorded and include a combination of didactics, interactive discussions, media use, and role play. The expected durations of session 1, 2-6, and the 3-month follow-up are 120 minutes, and 60-90 minutes, respectively.
Study: NCT01144182

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive quality improvement program (QIP)
Description: Comprehensive quality improvement program (QIP) that intervenes on patient, provider and system levels. The QIP will consist of 3 monthly phone calls to promote diet and medication adherence using the transtheoretical model as a behavioral framework and checklists to facilitate patients' self-monitoring of their diet, physical activity, weight and medication taking. Further, providers during the posttest phase will use checklists for inpatient and outpatient care of HF patients.
Study: NCT06123585

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Invisalign® SmileView™
Description: Pretreatment smiles were captured using the Invisalign® SmileView™ to simulate their new smiles before treatment was started.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Invisalign aligners
Description: Patients were then treated using upper and lower Invisalign aligners with average treatment time of 12±3 months.
Study: NCT03360396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endobronchial Coils
Description: Endobronchial Coil implants
Study: NCT02323802

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational group intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: prescriptive diet
Study: NCT02266849

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loperamide
Description: 12 mg Loperamide each day for three days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 tablets daily for three days
Study: NCT02270749

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxocobalamin
Description: patients are treated for 6 months with hydroxocobalamin. Patients will be treated with once a dose of 2000ug, after that treatment will be continued with a dose of 1000ug per 2 months. At timepoint 0, 2, 4 and 6 months after treatment vitamin B12 will be measured. At timepoint 0 and 6 also homocystein and methylmalonic acid will be measured.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FitForMe vitamin B12
Description: patients are treated for 6 months with a daily dose of 1000ug vitamin B12 tablets. At timepoint 0, 2, 4 and 6 months after treatment vitamin B12 will be measured. At timepoint 0 and 6 also homocystein and methylmalonic acid will be measured.
Study: NCT02629250

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: SV maximization
Description: When SpO2 ≥92%, mean arterial pressure (MAP) 65-100 mmHg, HR \<100 bpm, Hb \>8mg/dL and temperature ≥36℃, the patients will receive a 250 ml Ringer's lactate solution in 5 min as a fluid challenge for stroke volume (SV) maximization. The fluid challenge will repeat until the SV failed to increase by a factor of 10%. A reassessment on the SV maximization will be taken every 30 minutes and to restart algorithm when increased SV \>10% or blood loss \>250ml. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: supernormal DO2
Description: Goal directed fluid therapy is administrated as group SV maximization. Then DO2I will be assessed. If at this stage the DO2I can not be greater than 600 mL/m2 (supernormal oxygen delivery goal), then dobutamine will be started at a dose of 2.5 μg/kg/min and increased by the same increment every 20 minutes until the described target is reached or until a maximal dose of 20 μg/kg/min is given. Dobutamine is decreased in dose or discontinued if the heart rate is above 100 beats per minute or shows signs of cardiac ischemia.
Study: NCT02284347

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetic Sinus Dilation System (NuVent™)
Description: NuVent navigation-guided balloon system may be used to locate and move tissue, bone or cartilaginous tissue obstructing the drainage pathways of the frontal, maxillary, and sphenoid sinuses that is scarred, granulated or previously surgically-altered to facilitate dilation of the sinus ostia.
Study: NCT00759278

Intervention type: PROCEDURE
Intervention: ultrasound evaluation in pregnancy
Description: Subjects enrolled will have a series of ultrasound evaluations to assess parameters in the study. Ultrasound is a non-invasive technique for creating images that does not use radiation and is routine in obstetrical practice

Intervention type: PROCEDURE
Intervention: ultrasound evaluation in pregnancy
Description: Subjects enrolled will have a series of ultrasound evaluations to assess parameters in the study. Ultrasound is a non-invasive technique for creating images that does not use radiation and is routine in obstetrical practice
Study: NCT01951287

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute beverage (water) consumption
Description: Acute beverage consumption includes water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute beverage (Black Coffee) consumption
Description: Acute beverage consumption includes black coffee.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute beverage (Orange Juice) consumption
Description: Acute beverage consumption includes Orange Juice..

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute beverage (Whole Milk) consumption
Description: Acute beverage consumption includes whole milk
Study: NCT04057365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01
Description: DKN-01 is believed to work by attaching to and inhibiting (stopping) a specific pathway in the cells that is responsible for processes such as cell growth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01
Description: DKN-01 is believed to work by attaching to and inhibiting (stopping) a specific pathway in the cells that is responsible for processes such as cell growth
Study: NCT02351180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone
Description: Inhaled steroid that may decrease airway inflammation and the risk of chronic rejection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will serve as a control treatment
Study: NCT00603356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-930 and erlotinib
Description: OSI-930 administered daily in combination with Erlotinib at increasing doses until disease progression or unacceptable toxicity
Study: NCT02930590

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternating low pressure mattress with air loss function
Description: IsoAir, Stryker, USA
Study: NCT01951287

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute beverage (2% Milk) consumption
Description: Acute beverage consumption includes 2% milk

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute beverage (Skim Milk) consumption
Description: Acute beverage consumption includes skim milk
Study: NCT02710591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimeporide
Description: Cohort 1:~50 mg TID in patients with a body weight ≤ 30kg at Baseline and 75 mg TID in patients with a body weight \> 30kg at Baseline~Cohort 2:~100mg TID in patients with a body weight ≤ 30kg at baseline and 150 mg TID in patients with a body weight \> 30kg at Baseline~Cohort 3:~150 mg TID in patients with a body weight ≤ 30kg at baseline and 200 mg TID in patients with a body weight \> 30kg at Baseline~Cohort 4:~200 mg TID in patients with a body weight ≤ 30kg at Baseline and 300 mg TID mg TID in patients with a body weight \> 30kg at Baseline
Study: NCT02849236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine (PECS bloc)
Description: Ropivacaine 3.75mg/mL~Injection of a local anesthetic between pectoral major and pectoral minor muscles
Study: NCT03833674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory Strength Training Block
Description: Respiratory strength training using a hand-held device that resists inspiration or expiration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AIH + Strength Training Block
Description: AIH followed by respiratory strength training.
Study: NCT04111887

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group-based therapy
Description: College students with depressive symptoms will be randomized to one of three conditions: 1) a cognitive behavioral prevention intervention, 2) a cognitive behavioral prevention intervention with counter-attitudinal elements or 3) an educational brochure control. We will test if the additional of counter attitudinal elements produces intervention effects when delivered to participants with sub threshold depressive symptoms.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Group-based therapy
Description: College students with depressive symptoms will be randomized to one of three conditions: 1) a cognitive behavioral prevention intervention, 2) a cognitive behavioral prevention intervention with counter-attitudinal elements or 3) an educational brochure control. We will test if the additional of counter attitudinal elements produces intervention effects when delivered to participants with sub threshold depressive symptoms.
Study: NCT02849236

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 mL saline 0.9%
Study: NCT02930590

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gel mattress
Description: IsoGel, Stryker, USA
Study: NCT01474915

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: Subject will receive 40 mg of Aprepitant versus placebo PO before anesthesia induction
Study: NCT02930590

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basic foam
Description: Standard hospital mattress
Study: NCT01071967

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-based nurse care management
Description: The community-based nurse care management program developed by Health Quality Partners uses nurses working in the community to provide the following integrated set of services to older adults with chronic illness over the long term in order to prevent avoidable complications of their diseases and aging; geriatric assessment, care coordination, health education, self-management coaching, weight management, physical activity, gait and balance training, medication adherence, care transition support, ongoing monitoring and symptom detection, collaborative problem solving with patients, families and health care providers.
Study: NCT03503630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COMPOUND 2055269
Description: COMPOUND 2055269 to be given every 2 weeks with chemotherapy for 6 cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiotherapy 25 Gy to be given on Days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX
Description: Given every 2 weeks for 6 cycles

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Mesorectal Excision
Description: Surgery to be done 2-3 weeks after last cycle of chemotherapy and COMPOUND 2055269
Study: NCT04481906

Intervention type: PROCEDURE
Intervention: Vaginal mesh for female cystocele
Description: Vaginal mesh procedures (e.g. Perigee) were susgested for women with POP-Q stage III or more cystocele
Study: NCT02619266

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture is the practice of inserting thin needles into specific points to improve health and well-being.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham Acupuncture
Description: Sham acupuncture is used as a control in scientific studies that test the efficacy of acupuncture in the treatment of various illness or disorders.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Acupuncture
Description: Sham acupuncture is used as a control in scientific studies that test the efficacy of acupuncture in the treatment of various illness or disorders.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol Acetate
Description: Megestrol Acetate 160mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo(Megestrol Acetate)
Description: Starch pill manufactured to mimic Megestrol Acetate 160mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo(Megestrol Acetate)
Description: Starch pill manufactured to mimic Megestrol Acetate 160mg tablet
Study: NCT03505099

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: onasemnogene abeparvovec-xioi
Description: A non-replicating recombinant AAV9 containing the complimentary deoxyribonucleic acid (cDNA) of the human SMN gene under the control of the cytomegalovirus (CMV) enhancer/chicken-β-actin-hybrid promoter (CB). The AAV inverted terminal repeat (ITR) has been modified to promote intramolecular annealing of the transgene, thus forming a double-stranded transgene ready for transcription.